Oculus Innovative Sciences Announces Record Monthly and Quarterly Prescription Data
06 July 2016 - 6:05PM
May 2016: Highest Monthly Prescriptions Filled in
Oculus’ History
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, OCLSW), a specialty
pharmaceutical company that develops and markets unique and
effective solutions for the treatment of dermatological conditions
and advanced tissue care, today announced record monthly and
quarterly prescriptions filled in the company’s dermatology
products.
The average “quarter over quarter” growth of Oculus’ number of
prescriptions was 25% for the last four quarters ended March 31,
2016. More specifically, the number of prescriptions filled
of all dermatology products were 3,767 for the March 2015 quarter,
5,666 for the June 2015 quarter, 7,162 for September 2015 quarter,
6,736 for December 2015 quarter and 8,624 for the March 2016
quarter.
For the month of May 2016, the number of prescriptions was
3,917, or 36% above the average monthly rate of 2,874 for the March
2016 quarter. The number of prescriptions filled for April 2016 and
May 2016 collectively totaled 7,304, compared to 8,624 for the
total March 2016 quarter. Part of the May increase is attributed to
higher prescriptions filled for Ceramax, a state-of-the-art skin
repair product that was launched in April 2016.
“U.S. dermatology growth has continued to be strong in the first
quarter of our new fiscal year," said Bob Miller, Oculus CFO. "Our
dermatology sales and marketing team has done a stellar job in
growing this business from zero with a limited budget beginning in
the fall of 2014. Following the old adage, the key to our
business success is the people and the team at Oculus. Our progress
further validates the wisdom of placing our primary corporate focus
on growing the U.S. dermatology markets with our own experienced
sales force. We anticipate our best dermatology prescription
quarter ending June 30, 2016. As we continue to execute on
our four-pronged growth strategy to launch one new product per
quarter, grow existing products, add new sales people in new
territories and increase prices gradually, we believe this strong
sales ramp will continue.”
Oculus announced a new strategic direction for the company two
years ago, focused on launching products into the U.S. dermatology
market with the company’s own direct sales force. This initiative
is led by dermatology veterans and boasts a seasoned direct sales
force—totaling more than 20 professionals—that market a strong
portfolio of seven effective, branded and innovative products.
About Oculus Innovative Sciences, Inc.Oculus
Innovative Sciences is a specialty pharmaceutical company that
develops and markets unique and effective solutions for the
treatment of dermatological conditions and advanced tissue care.
The company’s products, which are sold throughout the United
States and internationally, have improved outcomes for more than
five million patients globally by reducing infections, itch,
pain, scarring and harmful inflammatory responses. The company's
headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. European
marketing and sales are headquartered in Roermond,
Netherlands. More information can be found at
www.oculusis.com
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Oculus Innovative
Sciences, Inc. and its subsidiaries (the “Company”). These
forward-looking statements are identified by the use of words such
as “continue,” “anticipate,” “execute,” and “market,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary,
including such risks that regulatory clinical and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not
be replicated in actual patient settings, protection offered
by the Company’s patents and patent applications may be
challenged, invalidated or circumvented by its
competitors, the available market
for the Company’s products will not be as large as
expected, the Company’s common stock and warrants may be delisted
from NASDAQ, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, the Company may
not be able to obtain additional funding, as well as uncertainties
relative to varying product formulations and a multitude of diverse
regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the
Company’s filings with the Securities and Exchange Commission
including its annual report on Form 10-K for the fiscal year
ended March 31, 2016. The Company disclaims any obligation to
update these forward-looking statements, except as required by
law.
Oculus and Microcyn® Technology are trademarks or registered
trademarks of Oculus Innovative Sciences, Inc. All other trademarks
and service marks are the property of their respective owners.
Media and Investor Contact:
Oculus Innovative Sciences, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024